Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited announced the quotation of 457,377 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its capital structure, potentially improving its market position and providing additional resources for its ongoing pharmaceutical development projects.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of pharmaceutical products. The company is primarily engaged in creating therapies for unmet medical needs, particularly in the areas of kidney disease and respiratory conditions.
Average Trading Volume: 3,224,904
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$332.2M
See more data about DXB stock on TipRanks’ Stock Analysis page.